<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04883840</url>
  </required_header>
  <id_info>
    <org_study_id>S63190</org_study_id>
    <nct_id>NCT04883840</nct_id>
  </id_info>
  <brief_title>Drug Repurposing - Statins as Microbiota Modulating Agents in Ulcerative Colitis</brief_title>
  <acronym>ReMiDy</acronym>
  <official_title>Drug Repurposing - Statins as Microbiota Modulating Agents in Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vlaams Instituut Biotechnologie (VIB)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  Evaluation of the microbiota modulation away from inflammation associated microbiota&#xD;
           profile Bacteroides2 (Bact2)&#xD;
&#xD;
        -  Evaluation of the microbiota modulation potential of statins in Bact2- enterotyped,&#xD;
           healthy volunteers and ulcerative colitis patients.&#xD;
&#xD;
        -  Evaluation of the effect of microbiota modulation on disease activity in ulcerative&#xD;
           colitis patients.&#xD;
&#xD;
        -  Evaluation of reduced inflammatory parameters of participants involved in trial&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 22, 2020</start_date>
  <completion_date type="Anticipated">December 22, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 22, 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>UC Mayo Score</measure>
    <time_frame>8 weeks</time_frame>
    <description>Decrease by a point during experimental intervention when taking IMP</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Systemic inflammatory measures</measure>
    <time_frame>8 weeks</time_frame>
    <description>significant and substantial decrease in hs-CRP when taking IMP</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Local inflammatory measures</measure>
    <time_frame>8 weeks</time_frame>
    <description>significant and substantial decrease fecal calprotectin when taking IMP</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Significant change in gastrointestinal microbiome composition</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change away from dysbiotic enterotype to eubiotic one when taking IMP</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Rosuvastatin 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin 10mg</intervention_name>
    <description>Daily dose of one medication over 8 week period then switch to another medication over an 8 week period (type of medication during each intervention period is blinded and then randomized).</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Rosuvastatin 10 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  General criteria&#xD;
&#xD;
               -  Bact2 enterotyped one month before start of study intervention (at least 150 of&#xD;
                  enrolled participants must meet this criteria)&#xD;
&#xD;
               -  Willingness to participate in the study and to sign the informed consent (Dutch)&#xD;
&#xD;
               -  Between 18 and 70 years old&#xD;
&#xD;
               -  Access to a -20Â°C freezer Criteria specific to UC patients&#xD;
&#xD;
               -  Patients in remission (mayo score below 4) or with currently mild to moderate&#xD;
                  active ulcerative colitis (defined by Mayo score of 4-10), despite stable&#xD;
                  medication (8 weeks) and a Mayo endoscopic sub-score 2- 3 at week 0 Criteria&#xD;
                  specific to healthy Bact2 participants&#xD;
&#xD;
               -  Individuals with no physician diagnosed diseases or disorders&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  General criteria&#xD;
&#xD;
               -  Prior and/or ongoing use of statins before study start&#xD;
&#xD;
               -  History of surgical intervention in gastrointestinal tract (appendectomies are&#xD;
                  allowed)&#xD;
&#xD;
               -  Females who are pregnant or actively trying to become pregnant&#xD;
&#xD;
               -  Individuals with active liver disease including unexplained persistent elevations&#xD;
                  of serum transaminases and any serum transaminases elevation exceeding three&#xD;
                  times the upper limit of normal (ULN)&#xD;
&#xD;
               -  Lactose intolerance&#xD;
&#xD;
               -  Pre-diabetic participants&#xD;
&#xD;
               -  Personal or family history of hereditary muscular disorders&#xD;
&#xD;
               -  Individuals with a history of or diagnosed with alcohol abuse Criteria specific&#xD;
                  to UC patients&#xD;
&#xD;
               -  Other conditions leading to profound immunosuppression such as HIV, infectious&#xD;
                  diseases leading to immunosuppression, bone marrow malignancies, liver cirrhosis&#xD;
&#xD;
               -  A diagnosis of Crohn's disease or indeterminate colitis&#xD;
&#xD;
               -  Individuals with hypothyroidism&#xD;
&#xD;
               -  Individuals with a diagnosis of diabetes mellitus&#xD;
&#xD;
               -  Individuals with severe renal impairment (creatinine clearance &lt;30 ml/min)&#xD;
&#xD;
               -  Individuals with myopathy&#xD;
&#xD;
               -  Participants who have taken antibiotics sometime in the past four months&#xD;
&#xD;
               -  Use of antibiotics one month prior to week 0&#xD;
&#xD;
               -  Steroid dependency and requiring &gt;16mg Medrol (methyl prednisone) or equivalent&#xD;
                  two week before week 0 Criteria specific to healthy Bact2 participants&#xD;
&#xD;
               -  Participants with family history of autoimmune chronic inflammatory diseases like&#xD;
                  multiple sclerosis, IBD, and rheumatoid arthritis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Severine Vermeire, MD &amp; PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>KU/UZ Leuven</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeroen Raes, PhD</last_name>
    <role>Study Director</role>
    <affiliation>KU Leuven/VIB</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tanine Daryoush, MS</last_name>
    <phone>+3216194080</phone>
    <email>tanine.daryoush@kuleuven.vib.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>Imelda Ziekenhuis</name>
      <address>
        <city>Bonheiden</city>
        <state>Antwerp</state>
        <zip>2820</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Peter Bossuyt, MD</last_name>
      <email>peter.bossuyt@imelda.be</email>
    </contact>
    <contact_backup>
      <last_name>Hanne Boey</last_name>
      <email>hanne.boey@imelda.be</email>
    </contact_backup>
    <investigator>
      <last_name>Peter Bossuyt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <state>Vlaams-Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Nigro, MS</last_name>
      <email>melissa.nigro@uzleuven.be</email>
    </contact>
    <contact_backup>
      <last_name>Tanine Daryoush, MS</last_name>
      <phone>+3216194080</phone>
      <phone_ext>Vermeire</phone_ext>
      <email>severine.vermeire@kuleuven.be</email>
    </contact_backup>
    <investigator>
      <last_name>Severine Vermeire, MD &amp; PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 6, 2021</study_first_submitted>
  <study_first_submitted_qc>May 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2021</study_first_posted>
  <last_update_submitted>May 6, 2021</last_update_submitted>
  <last_update_submitted_qc>May 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Microbiome</keyword>
  <keyword>Dysbiosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

